Seelos TherapeuticsSEELQ
13F holders, Q2 2024 (June 30)2holders −34
0new positions
14sold out
$0.62avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Seelos Therapeutics Inc. (SEELQ) in their 13F filings, down 34 from Q1 2024. 0 opened new positions and 14 sold out. The largest holders were Hollencrest Capital Management ($6) and Parallel Advisors, LLC ($2).
- Company
- Seelos Therapeutics Inc.
- CUSIP
- 81577F208
- Latest filing quarter
- Q2 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 14 | $718K |
All 13F filers, Q1 2024 → Q2 2024: 1,214,860 shares sold, net −1,214,860 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Hollencrest Capital Management | 0.00% | Reduce -88.4% | 10 | $6 |
| Parallel Advisors, LLC | 0.00% | Reduce -89.3% | 3 | $2 |
"% of holder's portfolio" is SEELQ's weight in each manager's 13F, not the share of Seelos Therapeutics Inc. the manager owns.